论文部分内容阅读
Dapagliflozin在治疗2型糖尿病的临床前期和临床期研究表明,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂增加肾糖排泄,可以降低血糖以及减轻体质量。大型试验论证了Dapagliflozin可能产生良好的效果而不出现重大不良反应,说明其具有安全性和有效性。因此,这类药物具有超过目前使用的许多降糖药的优势。现就SGLT2在糖代谢方面的作用和目前Dapagliflozin在治疗糖尿病中的应用进行综述。
Preclinical and clinical studies of Dapagliflozin in the treatment of type 2 diabetes have shown that inhibitors of sodium-glucose cotransporter 2 (SGLT2) increase renal glucose excretion, lowering blood glucose and reducing body weight. Large trials demonstrate that Dapagliflozin may produce good results without significant adverse effects, indicating its safety and efficacy. Therefore, such drugs have the advantage over many hypoglycemic agents currently in use. Now on the role of SGLT2 in glucose metabolism and the current application of Dapagliflozin in the treatment of diabetes were reviewed.